Last reviewed · How we verify
The SARS-CoV-2 Inactivated Vaccine
At a glance
| Generic name | The SARS-CoV-2 Inactivated Vaccine |
|---|---|
| Also known as | CoronaVac |
| Sponsor | Sinovac Research and Development Co., Ltd. |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- An Open Comparative Study of the Effectiveness and Incomparable Study of the Immunogenicity and Safety of the Vaccine (CoviVac) for Adults Aged 60 Years and Older (PHASE2)
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda (PHASE2)
- Covid-19 and Influenza Oral Vaccine Study (PHASE1)
- Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine (PHASE2)
- Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children (PHASE4)
- Clinical Trial of Safety and Immunogenicity of Recombinant SARS-CoV-2 S-Trimer Vaccine (CHO Cells) as Booster Vaccination in Populations Aged 18 to 59 Years (EARLY_PHASE1)
- Booster Study of COVID-19 Protein Subunit Recombinant Vaccine (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: